不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
滤泡性淋巴瘤：当前治疗格局与未来前景
英文原题：Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects.
查看英文原题
Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
滤泡性淋巴瘤的治疗已取得显著进展，使患者的长期结局得到改善。然而，该疾病的异质性给在治疗的每个阶段选择最佳疗法带来了挑战。不断扩展的治疗选择带来了新的复杂性，包括做出正确的初始选择、有效地安排治疗顺序以及重新定义治疗目标。随着治疗格局的演变，越来越需要转向基于精准的治疗决策，这可能由潜在的疾病生物学所指导。在此，我们探讨了一线治疗和复发/难治性治疗策略的最新进展，讨论了治疗选择中的考量因素，以及当前在精准方法方面的进展及其增强决策的潜力。
展开英文摘要原文
Significant strides have been made in the treatment of follicular lymphoma, leading to improvements in long-term patient outcomes.
However, the disease's heterogeneity presents challenges in selecting the optimal therapy at each stage of treatment. The expanding array of therapeutic options introduces new complexities, including making the right initial choice, sequencing treatments effectively, and redefining treatment goals. As the landscape evolves, there is a growing need to shift toward precision-based treatment decisions, potentially guided by underlying disease biology.
Here, we explore recent advancements in both upfront and relapsed/refractory treatment strategies, addressing considerations in therapy selection, and the current progress toward precision approaches with its potential to enhance decision-making.
论文信息
- 作者
- Kumar E、Okosun J
- 第一作者单位
- Department of Haematology, King's College Hospital, London, UK.United Kingdom
- 通讯作者单位
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.United Kingdom
- 文献类型
- 综述
- 期刊
- Hematological oncology2025 Jun
- 原文标识
- PubMed 40517443 · DOI 10.1002/hon.70070
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →